In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity
- 1 November 2007
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 75 (11) , 5443-5452
- https://doi.org/10.1128/iai.00529-07
Abstract
Passive transfer of antibody may be useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bacillus anthracis. Studies were performed to evaluate the ability of anthrax antiprotective antigen (anti-PA) and antilethal factor (anti-LF) neutralizing monoclonal antibodies (mAbs) to protect against an anthrax lethal toxin (LeTx) challenge in a mouse model and to identify correlates of immunity to LeTx challenge. Despite having similar affinities for their respective antigens, anti-PA (3F11) and anti-LF (9A11), passive transfer of up to 1.5 mg of anti-PA 3F11 mAb did not provide significant protection when transferred to mice 24 h before LeTx challenge, while passive transfer of as low as 0.375 mg of anti-LF 9A11 did provide significant protection. Serum collected 24 h after passive transfer had LeTx-neutralizing activity when tested using a standard LeTx neutralization assay, but neutralization titers measured using this assay did not correlate with protection against LeTx challenge. However, measurement of LeTx-neutralizing serum responses with an LeTx neutralization assay in vitro employing the addition of LeTx to J774A.1 cells 15 min before the addition of the serum did result in neutralization titers that correlated with protection against LeTx challenge. Our results demonstrate that only the LeTx neutralization titers measured utilizing the addition of LeTx to J774A.1 cells 15 min before the addition of sample correlated with protection in vivo. Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies.Keywords
This publication has 70 references indexed in Scilit:
- Capric Acid and Hydroxypropylmethylcellulose Increase the Immunogenicity of Nasally Administered Peptide VaccinesAIDS Research and Human Retroviruses, 2006
- An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbitsVaccine, 2006
- Protective Antigen and Toxin Neutralization Antibody Patterns in Anthrax Vaccinees Undergoing Serial PlasmapheresisClinical and Vaccine Immunology, 2005
- Human-derived, plant-produced monoclonal antibody for the treatment of anthraxVaccine, 2005
- Late Treatment with a Protective Antigen–Directed Monoclonal Antibody Improves Hemodynamic Function and Survival in a Lethal Toxin–Infused Rat Model of Anthrax SepsisThe Journal of Infectious Diseases, 2005
- A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore ChallengeInfection and Immunity, 2005
- Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Human antibodies from immunized donors are protective against anthrax toxin in vivoNature Biotechnology, 2003
- Anthrax ToxinCritical Reviews in Microbiology, 2001
- The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteinsArchiv für die gesamte Virusforschung, 1992